PONDERPelvic Peritonectomy for Early Stage Ovarian Tumors
This study is designed to determine whether pelvic peritonectomy can effectively detect microscopic implants in patients with early-stage ovarian tumors.
systematic surgical approach to wider peritoneal biopsies according with dissection of retroperitoneal spaces, nerve-sparing approach
+ Histopathologic Analysis
Urogenital Diseases+12
+ Genital Diseases
+ Adnexal Diseases
Diagnostic Study
Summary
Study start date: February 1, 2026
Actual date on which the first participant was enrolled.This study is designed to explore a surgical technique for early stage ovarian tumors. Specifically, it examines a method called pelvic peritonectomy, where certain areas of the pelvic lining are carefully removed. This technique aims to enhance the detection of very small cancerous growths that might not be visible otherwise. Identifying these growths is crucial because it could help prevent the cancer from returning in the pelvis. Women with early-stage ovarian cancer may benefit from this study as it seeks to improve surgical outcomes and inform future treatment approaches. Participants in the study will undergo an interventional procedure where surgeons will meticulously remove specific areas of the pelvic lining and examine the tissue for any hidden cancer cells. This process involves a careful dissection to preserve important nerves, aiming to minimize side effects. The study will measure the success of this technique by assessing how often these hidden cancer cells are found in the tissue samples taken during surgery. Understanding these findings can lead to better strategies for preventing the recurrence of ovarian cancer.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.390 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Age ≥ 18 years * FIGO 2018 stage IA-IB epithelial or non-epithelial ovarian or fallopian tube tumors * Complete preoperative work-up (ultrasound, CT scan, tumor markers) * Laparoscopic, robotic or open surgical approach * Signed informed consent Exclusion Criteria: * Sarcomas, melanomas, mesotheliomas, hematologic malignancies * Advanced ovarian tumors * Fertility-sparing surgery with uterine preservation * Inability to provide informed consent
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Azienda Ospedaliera Santa Croce e Carle Cuneo
Cuneo, ItalyOpen Azienda Ospedaliera Santa Croce e Carle Cuneo in Google Maps